Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 6, 2009, Pages 730-740

  Montesinos, Pau ^a   Sanz, Jaime ^a   Cantero, Susana ^a   Lorenzo, Ignacio ^a   Martín, Guillermo ^a   Saavedra, Silvana ^a   Palau, Javier ^a   Romero, Mónica ^a   Montava, Alberto ^a   Senent, Leonor ^a   Martínez, Jesús ^a   Jarque, Isidro ^a   Salavert, Miguel ^a   Córdoba, Juan ^a   Gómez, Lola ^a   Weiss, Shirley ^a   Moscardó, Federico ^a   de la Rubia, Javier ^a   Larrea, Luis ^b   Sanz, Miguel A ^a   Sanz, Guillermo F ^a   more..

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Centro de Transfusion de la Comunidad Valenciana   (Spain)

Author keywords

Cytomegalovirus; Ganciclovir; Prophylaxis; Umbilical cord blood transplantation; Valganciclovir

Indexed keywords

ACICLOVIR; BUSULFAN; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THIOTEPA; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENGRAFTMENT; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS PNEUMONIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT VS HOST DISEASE; HEALTH RESOURCES; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; PROGNOSIS; RISK FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67349276054     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.03.002     Document Type: Article

References (46)

1. Boeckh M., Nichols W.G., Papanicolaou G., et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9 (2003) 543-558
2. Zaia J.A. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 35 (2002) 999-1004
3. Brown J.A., and Boussiotis V.A. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol 127 (2008) 286-297
4. Walker C.M., van Burik J.A., De For T.E., et al. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 13 (2007) 1106-1115
5. Tomonari A., Takahashi S., Ooi J., et al. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. Eur J Haematol 80 (2008) 251-257
6. Takami A., Mochizuki K., Asakura H., et al. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. Haematologica 90 (2005) 1290-1292
7. Parody R., Martino R., Rovira M., et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 12 (2006) 734-748
8. Matsumura T., Narimatsu H., Kami M., et al. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients. Biol Blood Marrow Transplant 13 (2007) 577-583
9. Meyers J.D., Flournoy N., and Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153 (1986) 478-488
10. Enright H., Haake R., Weisdorf D., et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 55 (1993) 1339-1346
11. Boeckh M., and Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103 (2004) 2003-2008
12. Ljungman P., Aschan J., Lewensohn-Fuchs I., et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 66 (1998) 1330-1334
13. Yanada M., Yamamoto K., Emi N., et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 32 (2003) 801-807
14. Goodrich J.M., Mori M., Gleaves C.A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325 (1991) 1601-1607
15. Einsele H., Ehninger G., Hebart H., et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86 (1995) 2815-2820
16. Goodrich J.M., Bowden R.A., Fisher L., et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118 (1993) 173-178
17. Winston D.J., Ho W.G., Bartoni K., et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118 (1993) 179-184
18. Boeckh M., Gooley T.A., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88 (1996) 4063-4071
19. Ljungman P., Reusser P., de la Camara R., et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 33 (2004) 1075-1081
20. Winston D.J., Baden L.R., Gabriel D.A., et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant 12 (2006) 635-640
21. Einsele H., Reusser P., Bornhäuser M., et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107 (2006) 3002-3008
22. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 (2004) 611-620
23. Ciancio G., Burke G.W., Mattiazzi A., et al. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant 18 (2004) 402-406
24. Pereyra F., and Rubin R.H. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 17 (2004) 357-361
25. van der Heiden P.L., Kalpoe J.S., Barge R.M., et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 37 (2006) 693-698
26. Ayala E., Greene J., Sandin R., et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37 (2006) 851-856
27. Busca A., de Fabritiis P., Ghisetti V., et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 9 (2007) 102-107
28. Volin L, Barkholt L, Nihtinen A, et al. An open-label randomised study of oral valganciclovir versus intravenous ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. 34th Annual Meeting of the European Group for Blood and Marrow Transplantation, Florence, Italy, March 30-April 2, 2008. Oral communication, p. 268.
29. Sanz G.F., Saavedra S., Planelles D., et al. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood 98 (2001) 2332-2338
30. Sanz G.F., Cantero S., Larrea L., et al. Long-term outcome and prognostic factors after single-unit umbilical cord-blood transplantation (UCBT) for adults with hematologic malignancies. Blood. (ASH Annu. Meet. Abstr.) 108 (2006) 3129
31. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
32. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
33. Albano M.S., Taylor P., Pass R.F., et al. Umbilical cord blood transplantation and cytomegalovirus: Posttransplantation infection and donor screening. Blood 108 (2006) 4275-4282
34. Pumannova M., Roubalova K., Vitek A., et al. Comparison of quantitative competitive polymerase chain reaction-enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation. Diagn Microbiol Infect Dis 54 (2006) 115-120
35. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
36. Gray R.J. A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
37. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc B 34 (1972) 187-220
38. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
39. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
40. Dixon W.J. BMDP Statistical Software (1990), University of California Press, Berkeley, CA
41. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91 (2006) 78-83
42. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101 (2003) 407-414
43. Broers A.E., van Der Holt R., van Esser J.W., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 95 (2000) 2240-2245
44. Roback J.D., Caliendo A.M., Newman J.L., et al. Comparison of cytomegalovirus polymerase chain reaction and serology for screening umbilical cord blood components. Transfusion 45 (2005) 1722-1728
45. Bowden R.A., Slichter S.J., Sayers M., et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86 (1995) 3598-3603
46. Tomonari A., Takahashi S., Ooi J., et al. Preemptive therapy with ganciclovir 5 mg/kg once daily for cytomegalovirus infection after unrelated cord blood transplantation. Bone Marrow Transplant 41 (2008) 371-376